Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2024-10-01 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Update on funding and preliminary results
Regulatory Filings Classification · 98% confidence The document is very short (3294 characters) and announces an 'Update on funding and preliminary results'. Crucially, it states that the 'preliminary financial results for the year ended 30 June 2024' are being prepared and the Group 'now expects to publish its report by the end of October.' This structure—announcing the status of an upcoming report rather than providing the full report content—fits the definition of a Report Publication Announcement (RPA). The presence of the RNS Number and the RNS distribution footer confirms it is a regulatory news service announcement, but RPA is more specific than the general RNS fallback because it explicitly discusses the publication timing of another document (the preliminary results).
2024-10-01 English
Progression of patient cohorts in PROTECT Trial
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and contains standard regulatory boilerplate language at the end, referencing RNS, the London Stock Exchange, and the Financial Conduct Authority. The content itself is an announcement regarding clinical trial progress (Phase I/IIa VLP Peanut PROTECT Trial updates, safety data, and expected biomarker analysis timelines). This type of immediate, non-periodic operational update that is distributed via the RNS system and does not fit into specific categories like 10-K, ER, or IR is best classified as a general Regulatory Filing or announcement. Since it is a specific operational update distributed via RNS, 'RNS' (Regulatory Filings) is the most appropriate general category, as it is not a formal financial report (like IR or 10-K) nor a specific announcement like a dividend (DIV) or management change (MANG).
2024-09-17 English
Update on funding
Capital/Financing Update Classification · 98% confidence The document is identified by the 'RNS Number' header and contains an 'Update on funding' announcement from Allergy Therapeutics plc, dated August 27, 2024. It details the extension of a loan facility (£5m draw) and mentions the availability of further uncommitted funding (£12.5m). This is a specific corporate action related to financing and working capital. Since it is an announcement of a financial update/event rather than a full periodic report (like 10-K or IR) or a general regulatory filing (RNS), the most appropriate category is 'Capital/Financing Update' (CAP). The document is short and serves as a direct announcement, not a comprehensive report.
2024-08-27 English
Trading update for the year ended 30 June 2024
Earnings Release Classification · 98% confidence The document is titled 'Trading update for the year ended 30 June 2024' and provides preliminary financial highlights (revenue expectations, cost reductions, cash position) and significant clinical trial updates (Peanut PROTECT trial, Grass MATA MPL trial). It explicitly states that Full Year Results will be announced later ('in late-September'). This structure—a preliminary announcement of financial performance and operational milestones ahead of the full report—is characteristic of an Earnings Release (ER). Although it contains detailed operational updates, its primary function here is to release key financial figures early. It is not the comprehensive Annual Report (10-K) or the Interim Report (IR), nor is it merely an announcement of a report (RPA). The presence of 'RNS Number' and the closing statement referencing RNS confirms it is a regulatory news service filing. FY 2024
2024-07-22 English
Appointment of Nominated Adviser and Sole Broker
Board/Management Information Classification · 99% confidence The document is a short announcement (2826 characters) distributed via RNS (Regulatory News Service) of the London Stock Exchange. The content announces the 'Appointment of Nominated Adviser and Corporate Broker' with immediate effect. This type of corporate action announcement, which is not a full financial report (like 10-K or IR) or a specific filing like Director's Dealing (DIRS) or Dividend Notice (DIV), fits best under the general regulatory announcement category, which is RNS, as per the definition: 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' Although it relates to corporate structure/advisors, it is not explicitly covered by MANG (Board/Management changes) or CAP (Financing Update). Therefore, RNS is the most appropriate fallback classification.
2024-07-22 English
Launch of new Company Long Term Incentive Plan
Remuneration Information Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding statement referencing RNS as the news service of the London Stock Exchange. The content details the adoption of a new Long Term Incentive Plan (LTIP), the grant of share options to PDMRs (Persons Discharging Managerial Responsibilities), and a change of name for the Nominated Adviser. The grant of options to executives (PDMRs) and the subsequent disclosure table detailing these transactions fall under insider dealing/executive compensation disclosures, but the primary nature of this specific filing is a general regulatory announcement disseminated via RNS. Since it announces internal corporate actions (LTIP adoption, option grants, adviser name change) and is distributed via the RNS system, it fits best as a general Regulatory Filing (RNS), which serves as the catch-all for such announcements not covered by more specific codes like DIRS (which focuses purely on director's dealing reports, whereas this is broader corporate action) or DEF 14A (Remuneration Information, which is usually a detailed proxy filing). Given the structure and source (RNS), RNS is the most appropriate classification.
2024-07-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.